Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Liraglutide vs Tirzepatide

Q: What is the difference between Liraglutide and Tirzepatide?

Liraglutide is a GLP-1 compound (Subcutaneous route) - Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Tirzepatide is a GLP-1 compound (Subcutaneous route) - Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

Q: Which has a longer half-life, Liraglutide or Tirzepatide?

Tirzepatide has the longest published plasma half-life (~5.0 days (120 h)), compared with Liraglutide (13 h).

Q: How often is each compound dosed in the research literature?

Liraglutide: once daily at a published dose range of 0.6–3 mg; Tirzepatide: once weekly at a published dose range of 2.5–15 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Liraglutide and Tirzepatide for research use?

Yes - Tirzepatide is available from New-U Research Compounds as lab-verified (>99% HPLC) compound.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

LIRAGLUTIDE

Liraglutide

GLP-1

GLP-1R

GLP1-RC-TZ

Tirzepatide

Dual receptor agonist

GLP-1R · GIPR

Key research differences

Liraglutide Tirzepatide Receptor profile GLP-1R GLP-1R · GIPR Development status Approved therapeutic molecule Approved therapeutic molecule Published half-life 13 h ~5.0 days (120 h) Research distinction Shorter-acting GLP-1R agonism Dual incretin agonism

Published research parameters

Liraglutide Saxenda, Victoza Tirzepatide Mounjaro, Zepbound View Tirzepatide → Receptor profile GLP-1R GLP-1R · GIPR Class GLP-1 Dual receptor agonist Plasma half-life 13 h ~5.0 days (120 h) Time to Cmax 11 h 36 h Development status Approved therapeutic molecule Approved therapeutic molecule Study context Regulatory label PK Regulatory label PK Primary publications FDA Saxenda USPI — half-life ~13 h (2023) FDA Mounjaro USPI — half-life ~5 days (120 h) (2024) Summary Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

View published study parameters

Liraglutide Saxenda, Victoza Tirzepatide Mounjaro, Zepbound View Tirzepatide → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once weekly Published dose range 0.6–3 mg 2.5–15 mg Published study regimen 0.6 → 1.2 → 1.8 → 2.4 → 3 mg 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg

Source references

FDA Saxenda USPI — half-life ~13 h

FDA prescribing information · 2023

FDA Saxenda USPI — half-life ~13 h (2023)

Pi-Sunyer X et al.

New England Journal of Medicine · 2015

Pi-Sunyer X et al., NEJM 373:11 (2015)

FDA Mounjaro USPI — half-life ~5 days (120 h)

FDA prescribing information · 2024

FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)

SURPASS-2 trial — NEJM 385:503

New England Journal of Medicine · 2021

SURPASS-2 trial — NEJM 385:503 (2021)

Urva S et al.

Clinical Pharmacokinetics · 2022

Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)

Frequently asked questions

What is the difference between Liraglutide and Tirzepatide?

Which has a longer half-life, Liraglutide or Tirzepatide?

How often is each compound dosed in the research literature?

Can you buy Liraglutide and Tirzepatide for research use?

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research